Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Research & Development: 2023-2024

Historic Research & Development for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to $13.3 million.

  • Artiva Biotherapeutics' Research & Development rose 19.40% to $13.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $50.3 million, marking a year-over-year change of. This contributed to the annual value of $50.3 million for FY2024, which is 0.15% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Research & Development of $13.3 million as of Q4 2024, which was down 1.53% from $13.5 million recorded in Q3 2024.
  • Over the past 5 years, Artiva Biotherapeutics' Research & Development peaked at $14.8 million during Q2 2023, and registered a low of $11.2 million during Q4 2023.
  • Its 2-year average for Research & Development is $12.8 million, with a median of $13.1 million in 2023.
  • Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Research & Development showed a top increase of 19.40% in 2024 and a maximum decrease of 16.51% in 2024.
  • Over the past 2 years, Artiva Biotherapeutics' Research & Development (Quarterly) stood at $11.2 million in 2023, then increased by 19.40% to $13.3 million in 2024.
  • Its Research & Development stands at $13.3 million for Q4 2024, versus $13.5 million for Q3 2024 and $12.3 million for Q2 2024.